Recycled Blood Superior to Banked Blood for Surgery
|
By LabMedica International staff writers Posted on 25 May 2014 |
Patients whose own red blood cells (RBCs) are recycled during cardiopulmonary bypass (CPB) surgery fare better than those who get transfusions from a blood bank, according to a new study.
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Latest Hematology News
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Channels
Clinical Chemistry
view channel
Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreMolecular Diagnostics
view channel
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







